Edesa Biotech, Inc. (EDSA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$7.79M

Year ended 2025-09-30

-$14.53M

Trailing 12 months to 2026-06-30

2014-08-31 EBITDA (USD) 2025-09-30

Period ended	EBITDA	Change YoY	Source filing
2025-09-30	-$7.79M	n/m	2025-12-12, From 2024-10-01
2024-09-30	-$6.83M	n/m	2025-12-12, From 2023-10-01
2023-09-30	-$9.04M	n/a	2024-12-13, From 2022-10-01
No annual figure between 2017-09-30 and 2023-09-30.
2017-09-30	-$5.05M	n/m	2018-11-30, From 2016-10-01
2016-09-30	-$4.76M	n/m	2017-12-01, From 2015-10-01
2015-09-30	-$4.18M	n/a	2017-12-01, From 2014-10-01
2014-08-31	-$5.56M	n/a	2016-12-14, From 2013-09-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Edesa Biotech, Inc. (EDSA)	2025-09-30	-$7.79M	n/m
CytoDyn Inc. (CYDY)	2026-05-31	-$38.56M	n/m
Exicure, Inc. (XCUR)	2025-12-31	-$3.99M	n/m
NRX Pharmaceuticals, Inc. (NRXP)	2025-12-31	-$16.15M	n/m
Imunon, Inc. (IMNN)	2024-12-31	-$18.89M	n/m
Cellectar Biosciences, Inc. (CLRB)	2025-12-31	-$22.77M	n/m
Turn Therapeutics Inc. (TTRX)	2025-12-31	-$5.81M	n/m
Aprea Therapeutics, Inc. (APRE)	2025-12-31	-$13.21M	n/m
NewcelX Ltd. (NCEL)	2025-12-31	-$2.51M	n/m

Compare EDSA, CYDY, XCUR, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗